title: Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry.
abstract: OBJECTIVE
  The prospective EUROVISION Registry was designed to capture patterns of use and short term outcomes in consecutive patients undergoing PCI with bivalirudin (BIV) in European centres.
  
  
  METHODS
  A total of 2018 consecutive BIV-treated patients were included from 58 sites in 5 countries (Germany, Italy, France, Austria, United Kingdom). In-hospital and 30-day outcomes were prospectively collected and included: death, myocardial infarction (MI), stroke, urgent revascularization (URV), major and minor bleeding, stent thrombosis (ST) and thrombocytopenia (TCP).
  
  
  RESULTS
  In this all-comer population, indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina (16%) and stable angina (26%). Diabetes was present in 24% of patients and 30% of cases were performed via radial access. Preloading with a P2Y12 inhibitor was frequent (74%) while procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Almost half (45%) of patients had received at least one additional anticoagulant prior to receiving BIV for PCI. The overall 30-day mortality was 1.0%, with low rates of MI (1.1%), URV (0.8%), ST (0.3%) and stroke (0.2%). The rate of ACUITY major bleeding was 1.6% and no TCP was reported. Dosing variations representing possible under- or over-dosing of BIV were frequent at 35%.
  
  
  CONCLUSIONS
  In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.
authors.affiliation: University of Caen, France; INSERM U 744, Lille, France. Electronic address: hamon-m@chu-caen.fr.
authors.forename: Martial
authors.initials: M
authors.lastname: Hamon
authors.affiliation: Heart Center Rostock, Rostock, Germany.
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Nienaber
authors.affiliation: Centro Cardiologico Monzino, IRCCS, University of Milan, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Galli
authors.affiliation: Medizinische Abteilung (Kardiologie) Wilhelminenspital Montleartstrasse, Wien, Austria.
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
authors.affiliation: Centre de Cardiologie Interventionnelle, Pôle Santé République, Clermont-Ferrand, France.
authors.forename: Janusz
authors.initials: J
authors.lastname: Lipiecki
authors.affiliation: King's College Hospital, Denmark Hill, London SE5 9RS, UK.
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Hill
authors.affiliation: Cardiology Department, Centre Marie Lannelongue, Le Plessis-Robinson, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Amabile
authors.affiliation: The Medicines Company, Parsippany, NJ, USA.
authors.forename: Debra
authors.initials: D
authors.lastname: Bernstein
authors.affiliation: The Medicines Company, Parsippany, NJ, USA.
authors.forename: Efthymios
authors.initials: E
authors.lastname: Deliargyris
authors.affiliation: INSERM U-970, AP-HP, Paris, France; Université Paris-Descartes, Paris, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Lafont
authors.affiliation: Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France; INSERM U-698, Paris, France; Hôpital Bichat, AP-HP, Paris, France.
authors.forename: Philippe Gabriel
authors.initials: PG
authors.lastname: Steg
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000188:drug therapy* / Q000401:mortality; D000789:Angina, Unstable / Q000188:drug therapy* / Q000401:mortality; D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use*; D003328:Coronary Thrombosis / Q000209:etiology / Q000401:mortality; D005060:Europe / Q000453:epidemiology; D005260:Female; D006470:Hemorrhage / Q000401:mortality; D006629:Hirudins; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality; D017063:Outcome Assessment, Health Care; D010446:Peptide Fragments / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000401:mortality / Q000706:statistics & numerical data*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012042:Registries / Q000706:statistics & numerical data; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D020521:Stroke / Q000401:mortality
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin
keywords: Antithrombin; Bivalirudin; PCI; STEMI; Stent thrombosis